Literature DB >> 33990663

Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimer's disease.

Zhaoyi Chen1, Hansi Zhang1, Yi Guo1, Thomas J George2, Mattia Prosperi3, William R Hogan1, Zhe He4, Elizabeth A Shenkman1, Fei Wang5, Jiang Bian6.   

Abstract

In this study, we explored the feasibility of using real-world data (RWD) from a large clinical research network to simulate real-world clinical trials of Alzheimer's disease (AD). The target trial (i.e., NCT00478205) is a Phase III double-blind, parallel-group trial that compared the 23 mg donepezil sustained release with the 10 mg donepezil immediate release formulation in patients with moderate to severe AD. We followed the target trial's study protocol to identify the study population, treatment regimen assignments and outcome assessments, and to set up a number of different simulation scenarios and parameters. We considered two main scenarios: (1) a one-arm simulation: simulating a standard-of-care (SOC) arm that can serve as an external control arm; and (2) a two-arm simulation: simulating both intervention and control arms with proper patient matching algorithms for comparative effectiveness analysis. In the two-arm simulation scenario, we used propensity score matching controlling for baseline characteristics to simulate the randomization process. In the two-arm simulation, higher serious adverse event (SAE) rates were observed in the simulated trials than the rates reported in original trial, and a higher SAE rate was observed in the 23 mg arm than in the 10 mg SOC arm. In the one-arm simulation scenario, similar estimates of SAE rates were observed when proportional sampling was used to control demographic variables. In conclusion, trial simulation using RWD is feasible in this example of AD trial in terms of safety evaluation. Trial simulation using RWD could be a valuable tool for post-market comparative effectiveness studies and for informing future trials' design. Nevertheless, such an approach may be limited, for example, by the availability of RWD that matches the target trials of interest, and further investigations are warranted.

Entities:  

Year:  2021        PMID: 33990663      PMCID: PMC8121837          DOI: 10.1038/s41746-021-00452-1

Source DB:  PubMed          Journal:  NPJ Digit Med        ISSN: 2398-6352


  25 in total

1.  Generalizability of findings from randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network.

Authors:  Ryoko Susukida; Rosa M Crum; Cyrus Ebnesajjad; Elizabeth A Stuart; Ramin Mojtabai
Journal:  Addiction       Date:  2017-03-16       Impact factor: 6.526

2.  Key cost drivers of pharmaceutical clinical trials in the United States.

Authors:  Aylin Sertkaya; Hui-Hsing Wong; Amber Jessup; Trinidad Beleche
Journal:  Clin Trials       Date:  2016-02-08       Impact factor: 2.486

Review 3.  The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.

Authors:  William James Deardorff; Eliahu Feen; George T Grossberg
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

4.  Donepezil dosing strategies: pharmacokinetic considerations.

Authors:  Irving H Gomolin; Candace Smith; Thomas M Jeitner
Journal:  J Am Med Dir Assoc       Date:  2011-03-31       Impact factor: 4.669

5.  Propensity Score Matching as a Substitute for Randomized Controlled Trials on Acute Kidney Injury After Contrast Media Administration: A Systematic Review.

Authors:  Ilona A Dekkers; Aart J van der Molen
Journal:  AJR Am J Roentgenol       Date:  2018-08-07       Impact factor: 3.959

6.  Assessing the Validity of a a priori Patient-Trial Generalizability Score using Real-world Data from a Large Clinical Data Research Network: A Colorectal Cancer Clinical Trial Case Study.

Authors:  Qian Li; Zhe He; Yi Guo; Hansi Zhang; Thomas J George; William Hogan; Neil Charness; Jiang Bian
Journal:  AMIA Annu Symp Proc       Date:  2020-03-04

Review 7.  High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines.

Authors:  Jeffrey L Cummings; David Geldmacher; Martin Farlow; Marwan Sabbagh; Daniel Christensen; Peter Betz
Journal:  CNS Neurosci Ther       Date:  2013-03-06       Impact factor: 5.243

8.  Assessing the generalizability of randomized trial results to target populations.

Authors:  Elizabeth A Stuart; Catherine P Bradshaw; Philip J Leaf
Journal:  Prev Sci       Date:  2015-04

9.  Emulating a Novel Clinical Trial Using Existing Observational Data. Predicting Results of the PreVent Study.

Authors:  Andrew J Admon; John P Donnelly; Jonathan D Casey; David R Janz; Derek W Russell; Aaron M Joffe; Derek J Vonderhaar; Kevin M Dischert; Susan B Stempek; James M Dargin; Todd W Rice; Theodore J Iwashyna; Matthew W Semler
Journal:  Ann Am Thorac Soc       Date:  2019-08

Review 10.  Synthetic and External Controls in Clinical Trials - A Primer for Researchers.

Authors:  Kristian Thorlund; Louis Dron; Jay J H Park; Edward J Mills
Journal:  Clin Epidemiol       Date:  2020-05-08       Impact factor: 4.790

View more
  2 in total

1.  Emulation of the control cohort of a randomized controlled trial in pediatric kidney transplantation with Real-World Data from the CERTAIN Registry.

Authors:  Christian Patry; Lukas D Sauer; Britta Höcker; Burkhard Tönshoff; Anja Sander; Kai Krupka; Alexander Fichtner; Jolanda Brezinski; Yvonne Geissbühler; Elodie Aubrun; Anna Grinienko; Luca Dello Strologo; Dieter Haffner; Jun Oh; Ryszard Grenda; Lars Pape; Rezan Topaloğlu; Lutz T Weber; Antonia Bouts; Jon Jin Kim; Agnieszka Prytula; Jens König; Mohan Shenoy
Journal:  Pediatr Nephrol       Date:  2022-10-20       Impact factor: 3.651

2.  The OneFlorida Data Trust: a centralized, translational research data infrastructure of statewide scope.

Authors:  William R Hogan; Elizabeth A Shenkman; Temple Robinson; Olveen Carasquillo; Patricia S Robinson; Rebecca Z Essner; Jiang Bian; Gigi Lipori; Christopher Harle; Tanja Magoc; Lizabeth Manini; Tona Mendoza; Sonya White; Alex Loiacono; Jackie Hall; Dave Nelson
Journal:  J Am Med Inform Assoc       Date:  2022-03-15       Impact factor: 4.497

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.